For the Inventor, By the Inventor

Enter assignee name

San Diego, CA, United States of America

Effector Therapeutics, Inc.

USPTO Granted Patents = 21

EPO Patents = 6

Trademarks = 3

Forward Citations = 71

Loading Chart...

Loading Chart...

24 inventors (with patents filed for the assignee):

Justin T Ernst (15 out of 21 patents)

Paul A Sprengeler (15 out of 15 patents)

Siegfried Heinz Reich (14 out of 50 patents)

4. Alan X Xiang (10 out of 18 patents)

5. Stephen Evan Webber (8 out of 54 patents)

6. Samuel Sperry (5 out of 5 patents)

7. Chinh Viet Tran (5 out of 34 patents)

8. Christian Nilewski (4 out of 4 patents)

9. Theo Michels (4 out of 4 patents)

10. Garrick Kenneth Packard (4 out of 20 patents)

11. Kevin R Webster (4 out of 4 patents)

12. Peggy A Thompson (3 out of 4 patents)

13. Mike Shaghafi (2 out of 2 patents)

14. Bennett C Borer (2 out of 14 patents)

15. Jo Ann Z Wilson (2 out of 2 patents)

21 patents: Sort by Forward Citations

1. 11952375 - Crystalline forms of Mnk inhibitors (2024-04-09),

2. 11878015 - Piperidine-substituted Mnk inhibitors and methods related thereto (2024-01-23),

3. 11576933 - Compositions and methods for an improved antitumor immune response (2023-02-14),

4. 11564947 - Methods and compositions for cellular immunotherapy (2023-01-31),

5. 11440917 - EIF4A-inhibiting compounds and methods related thereto (2022-09-13),

6. 11286268 - EIF4E-inhibiting compounds and methods (2022-03-29),

7. 11130757 - Crystalline forms of MNK inhibitors (2021-09-28),

8. 11083727 - Piperidine-substituted Mnk inhibitors and methods related thereto (2021-08-10),

9. 11014926 - Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds that inhibit MNK1 and MNK2 (2021-05-25),

10. 10793551 - Benzimidazole-indole inhibitors of Mnk1 and Mnk2 (2020-10-06),

11. 10780119 - Methods and compositions for cellular immunotherapy (2020-09-22),

12. 10702526 - Inhibitors of immune checkpoint modulators and related methods (2020-07-07),

13. 10577378 - EIF4A-inhibiting compounds and methods related thereto (2020-03-03),

14. 10576098 - Compositions and methods for treating fibrotic disease (2020-03-03),

15. 10112955 - Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of Mnk1 and Mnk2 (2018-10-30),

Effector Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel small molecule therapies in the field of oncology. Their proprietary technology platform enables the discovery of selective covalent drugs that target key nodes of the cancer signaling network to drive tumor cell death. Effector's lead candidate is currently in clinical trials for various types of cancer.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

21 Patents

#271 in San Diego, CA

#3,627 in California

#15,183 in US

#29,080 in the World

San Diego, CA, United States of America

Effector Therapeutics, Inc.

Forward Citations = 71

24 inventors:

Justin T Ernst (15 out of 21 patents)

Paul A Sprengeler (15 out of 15 patents)

Siegfried Heinz Reich (14 out of 50 patents)

4. Alan X Xiang (10 out of 18 patents)

5. Stephen Evan Webber (8 out of 54 patents)

Please report any incorrect information to support@idiyas.com

Loading…